Aurinia Sues Lotus Alleging Lupus Drug Patent Infringement

By Adam Lidgett · April 11, 2025, 7:27 PM EDT

Kidney-focused biotech Aurinia Pharmaceuticals Inc. on Friday launched a lawsuit in New Jersey federal court claiming that Lotus Pharmaceutical Co. Ltd.'s bid to sell a generic form of Aurinia's lupus nephritis...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

AURINIA PHARMACEUTICALS INC. v. LOTUS PHARMACEUTICAL CO., LTD.

Case Number

Court

New Jersey

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

April 11, 2025

Recent Articles By Adam

April 11, 2025
Foreign Cos. Say Anti-Choking Device Patent Is Invalid
April 08, 2025
Pacira Reaches IP Deal Allowing Generic Painkiller In 2030
April 07, 2025
Incyte Can't Get Pretrial Win In Novartis Royalty Fight
April 03, 2025
Texas Appeals Court Backs UT Royalty Award In Pet Co. Suit
March 27, 2025
Fitch Even Sues Ex-IP Client In Effort To End Malpractice Case
March 24, 2025
Amgen Wants $50M Leukemia Drug Patent Verdict Thrown Out
March 18, 2025
Bausch Eye Vitamin Case Should Go To Jury, Judge Says
March 18, 2025
AI Healthcare Co. Accuses Test-Maker Of Infringing Patents
January 22, 2025
Vanda Loses Takings Clause Arguments In Trade Secret Fight
January 06, 2025
Biotech Trade Secrets Case Gets New Punitive Damages Trial